Full Year 2025 Genus PLC Earnings Call Transcript
Key Points
- Genus PLC (GENSF) achieved strong financial results with a 30% increase in group adjusted operating profit in constant currency.
- The company reported a significant milestone with the US FDA approval of their PRP gene edit, marking a major achievement in their R&D program.
- Genus PLC (GENSF) is accelerating its joint venture formation in China, securing a $160 million gross cash payment and a $7.5 million milestone payment.
- The ABS value acceleration program has delivered substantial benefits, with Phases I and II achieving over GBP21 million of annualized benefit.
- The company generated record free cash flow, covering dividends and reducing debt, with a strong balance sheet and debt leverage down to 1.5 times EBITDA.
- Genus PLC (GENSF) faced a significant GBP8.5 million FX headwind due to Sterling strength, impacting financial results.
- The European business was negatively impacted by ongoing health challenges in customer herds, affecting performance.
- In China, the market environment for dairy producers remains challenging, with restrictions on US bovine genetics imports posing additional challenges.
- ABS performance in Latin America was weak, with a 6% decline in beef genetics volume due to a weak market in Brazil.
- Exceptional expenses were significant, including GBP24.2 million in cash outflows related to restructuring and corporate transactions.
Thank you for joining us this morning. My name is Jorgen Kokke, and I'm the Genus CEO. First, I am delighted to introduce Andy Russell, our new CFO, who has succeeded Alison Henriksen on the August 1, and a bit more about Andy will follow later. I'm also very pleased to report that we've made a significant announcement this morning related to the acceleration of our porcine joint venture formation in China.
Andy and I will take you through Genus' results for the year, which will be followed by a presentation on our China JV. In summary, we have achieved strong financial results and made significant strategic progress. I'd like to take the opportunity to thank all Genus employees for their contributions in achieving these results. After the disclaimer, let me start with an overview of our strategic performance as well as our key financial headlines.
Our three strategic priorities remain unchanged. Our first priority is continued growth in porcine. I am pleased to report that PIC, excluding China, achieved an 11%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
